司美格鲁肽治疗抗精神病药治疗的精神分裂症、糖尿病前期和肥胖患者:HISTORI随机临床试验
该多中心、双盲、安慰剂对照随机临床试验纳入154例接受第二代抗精神病药治疗的精神分裂症、糖尿病前期和超重/肥胖成人,每周皮下注射司美格鲁肽(滴定至1.0 mg/周)或安慰剂30周。司美格鲁肽显著降低HbA1c和体重,改善高密度脂蛋白胆固醇、甘油三酯和躯体生活质量,未恶化精神症状或精神生活质量,胃肠道症状更常见。
要点
- 司美格鲁肽30周降低HbA1c 0.46%和体重9.21 kg,81% vs 19%患者HbA1c达标(P<.001)。
- 司美格鲁肽改善高密度脂蛋白胆固醇、甘油三酯和SF-36v2躯体生活质量,未恶化PANSS-6或精神生活质量。
- 胃肠道症状在司美格鲁肽组更常见,严重不良事件数两组无差异。
核心结论
- 在接受第二代抗精神病药治疗的精神分裂症、糖尿病前期和肥胖患者中,司美格鲁肽每周1.0 mg治疗30周安全,降低血糖和体重,改善躯体生活质量,不恶化精神健康。
研究设计与样本
- 多中心、安慰剂对照、双盲随机临床试验,2022年1月至2024年5月在丹麦两个地区社区精神卫生服务机构进行,随访30周。
- 共招募154例接受第二代抗精神病药治疗的精神分裂症、糖尿病前期(HbA1c 5.7%-6.4%)和超重/肥胖(BMI≥27)的成人(18-60岁),1:1随机分配至司美格鲁肽或安慰剂组。
- 司美格鲁肽每周皮下注射,8周内滴定至1.0 mg/周,主要结局为HbA1c变化。
主要发现
- 司美格鲁肽降低HbA1c 0.46%(95% CI, -0.56%至-0.36%)和体重9.21 kg(95% CI, -11.68至-6.75)。
- HbA1c低于5.7%的患者比例司美格鲁肽组81% vs 安慰剂组19%(P < .001)。
- 司美格鲁肽改善高密度脂蛋白胆固醇10.81 mg/dL(95% CI, 2.70-18.53; P = .007)和甘油三酯-29.20 mg/dL(95% CI, -55.75至2.65; P = .03)。
- 司美格鲁肽改善SF-36v2躯体生活质量3.75分(95% CI, 1.52-5.98; P = .001),对精神生活质量评分或PANSS-6评分无显著影响。
- 胃肠道症状在司美格鲁肽组更频繁;少数司美格鲁肽组患者住院更频繁,但严重不良事件数两组无差异。
关键数值与推荐
- 糖尿病前期定义为HbA1c 5.7%-6.4% of total hemoglobin。
- 超重或肥胖定义为BMI ≥27(体重kg除以身高m的平方)。
- 司美格鲁肽剂量8周内滴定至1.0 mg/周,治疗30周。
临床怎么用
- 对于接受第二代抗精神病药治疗的精神分裂症合并糖尿病前期和肥胖患者,可考虑使用司美格鲁肽1.0 mg/周改善血糖、体重和躯体生活质量。
- 使用司美格鲁肽时需监测胃肠道症状,但严重不良事件风险未见显著增加。
- 司美格鲁肽未恶化精神症状(PANSS-6)或精神生活质量,但需关注个别患者住院频率。
局限性
- 研究人群限于丹麦两个地区,随访30周,长期疗效和安全性未评估。
- 样本量154例,部分亚组分析可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with schizophrenia have reduced life expectancy due to cardiovascular disease and obesity-related type 2 diabetes, exacerbated by second-generation antipsychotic (SGA) medication. Existing interventions have shown limited effect. OBJECTIVES: To assess the effect of the once-weekly glucagon-like peptide-1 receptor agonist semaglutide in SGA-treated adults (aged 18-60 years) with schizophrenia, prediabetes (glycosylated hemoglobin A1c [HbA1c], 5.7%-6.4% of total hemoglobin) (to convert HbA1c from percentage of total hemoglobin to mmol/mol, use the following formula: (HbA1c % - 2.152)/0.09148), and overweight or obesity (body mass index [BMI], calculated as weight in kilograms divided by height in meters squared, ≥27). DESIGN, SETTING, AND PARTICIPANTS: This placebo-controlled, double-blinded randomized clinical trial was conducted from January 2022 to May 2024, with 30 weeks of follow-up, among regional community-based mental health services in 2 regions of Denmark (Region of Southern Denmark and Region of Zealand). SGA-treated patients with schizophrenia, prediabetes, and overweight or obesity were randomized to semaglutide or placebo. Data analysis was completed from May 2024 to January 2025. INTERVENTION: Once-weekly subcutaneous semaglutide or placebo for 30 weeks; semaglutide was titrated up to 1.0 mg/week over 8 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was change in HbA1c. Secondary end points included changes in body weight, schizophrenia symptoms based on Positive and Negative Syndrome Scale 6 (PANSS-6) score, and physical and mental quality of life (QoL) (assessed via the 36-item Short Form Survey, version 2 [SF-36v2]). RESULTS: A total of 154 patients were recruited and randomized 1:1 to semaglutide or placebo (87 female participants (56.5%); mean [SD] age, 38.3 [10.7] years). Of 154 randomized patients, 141 (91.5%) completed the trial-74 of 77 patients randomized to semaglutide (96%) and 67 of 77 randomized to placebo (87%). Semaglutide reduced HbA1c by 0.46% of total hemoglobin (95% CI, -0.56% to -0.36%) and body weight by 9.21 kg (95% CI, -11.68 to -6.75). An HbA1c less than 5.7% of total hemoglobin was achieved in 81% vs 19% of patients treated with semaglutide and placebo, respectively (P < .001); improvements in high-density cholesterol by 10.81 mg/dL (95% CI, 2.70-18.53; P = .007) and triglycerides by -29.20 mg/dL (95% CI, -55.75 to 2.65; P = .03) (to convert to millimoles per liter, multiply by 0.0113) were also observed. Finally, semaglutide improved physical QoL by 3.75 points on the SF-36v2 (95% CI, 1.52-5.98; P = .001) but had no significant effect on mental QoL scores or PANSS-6 score. Gastrointestinal symptoms were more frequent in semaglutide-treated patients. A few semaglutide-treated patients were hospitalized more frequently than observed in the placebo-treated group, but the number of serious adverse effects did not differ between groups. CONCLUSIONS AND RELEVANCE: In this multicenter, double-blinded randomized clinical trial, 30 weeks of administration of semaglutide, up to 1.0 mg/week, was safe, lowered blood glucose (as measured by HbA1c) and weight, and improved physical QoL in SGA-treated patients with schizophrenia, prediabetes, and obesity without worsening mental health. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05193578.
引用
- Ganeshalingam AA, Uhrenholt N, Arnfred S, et al. Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 40900607. doi:10.1001/jamapsychiatry.2025.2332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。